SCHEMBL10272934

SCHEMBL10272934

CCc1cc2c(cn1)CCCC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.50
NOS1 P29475 1/20 0.50
NOS2 P35228 1/20 0.50
HTR2B P41595 1/20 0.40
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
SIGMAR1 Q99720 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
CYP1A2 P05177 3/20 0.33
CYP2D6 P10635 1/20 0.33
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
GLA P06280 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24221641 0.98 NOS3 (0.48) NOS3NOS1NOS2HTR2BCDK5
SCHEMBL25061140 0.98 NOS3 (0.48) NOS3NOS1NOS2HTR2BCDK5
SCHEMBL11984396 0.96 NOS3 (0.45) NOS3NOS1NOS2HTR2BCDK5
SCHEMBL25574578 0.79 NOS3 (0.55) NOS3NOS1NOS2HTR2BSIGMAR1
SCHEMBL3328642 0.79 NOS3 (0.50) NOS3NOS1NOS2HTR2BSIGMAR1
SCHEMBL23091837 0.79 NOS3 (0.50) NOS3NOS1NOS2HTR2BSIGMAR1
SCHEMBL29569615 0.79 NOS3 (0.50) NOS3NOS1NOS2HTR2BSIGMAR1
SCHEMBL8567874 0.76 NOS3 (0.47) NOS3NOS1NOS2HTR2BSIGMAR1
SCHEMBL8565852 0.76 NOS3 (0.47) NOS3NOS1NOS2HTR2BSIGMAR1
SCHEMBL24804486 0.76 PIK3CD (0.33) HTR2BCYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024173343-A1 COMPOUNDS TARGETING HYDROXYSTEROID 17-BETA DEHYDROGENASE (HSD17B) AND USES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2024-08-22 WO disclosed
US-11306088-B2 CXCR4 inhibitors and uses thereof X4 PHARMACEUTICALS, INC. (US) 2022-04-19 US disclosed
US-20210047320-A1 CXCR4 INHIBITORS AND USES THEREOF X4 PHARMACEUTICALS, INC. 2021-02-18 US disclosed
US-20150094309-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL MYERS SQUIBB CO (US) 2015-04-02 US disclosed
US-20130131064-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2013-05-23 US disclosed
US-20120035189-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2012-02-09 US disclosed
US-7576098-B2 Heterocyclic compounds as inhibitors of factor VIIa BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210047320-A1 CXCR4 INHIBITORS AND USES THEREOF CXCR4, CXCL12, CXCR3 NOS3 3466/4885NOS1 3823/4885NOS2 3693/4885
US-20120035189-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 NOS3 2801/4885NOS1 2447/4885NOS2 3530/4885
US-20130131064-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 NOS3 2801/4885NOS1 2447/4885NOS2 3530/4885
US-20150094309-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA6 NOS3 2801/4885NOS1 2447/4885NOS2 3530/4885
US-11306088-B2 CXCR4 inhibitors and uses thereof CXCR4, CXCL12, CXCR3 NOS3 3466/4885NOS1 3823/4885NOS2 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.